LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer

NCT01757327 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Poor accrual

Conditions

Breast Neoplasms

Interventions

DRUG: Erismodegib
DRUG: Placebo

Sponsor

Washington University School of Medicine